À̹ÌÁö È®´ë CHA Vaccine Institute, a Korean research-oriented biotechnology firm, has developed a new vaccine adjuvant that can be applied to preventive and therapeutic vaccines against various infections and diseases.
During an interview with Maeil Business Newspaper last week, the company¡¯s chief executive Yum Jung-sun said CHA Vaccine Institute is working on a `premium vaccine` based on its immune enhancement platform technology called L-pampo.
Adjuvants are substances that increase the immunogenicity of vaccine antigens. Unlike existing adjuvants, L-pampo is able to induce both humoral immune response such as antibodies and cellular immune response, which can kill viral antigens, Yum explained.
À̹ÌÁö È®´ë Yum Jung-sun
In April last year, CHA Vaccine Institute signed a technology transfer deal to apply its adjuvant technology to an investigational Covid-19 vaccine being developed by China¡¯s CanSino Biologics. Last month CHA Vaccine Institute sealed a $200 million deal to license out its technology to Aston Science, a Korean pharmaceutical company.
CHA Vaccine is developing therapeutic vaccines based on its adjuvant technology. Its pipeline includes a hepatitis B treatment vaccine, which is in phase 2b clinical trial. This vaccine is designed to cure chronic hepatitis B by removing the virus, Yum said.
CHA Vaccine Institute is also cooperating with CanSino to develop a Covid-19 vaccine with a goal of entering a phase 1 trial within this year.
Yum said CHA Vaccine Institute will file a preliminary review application for initial public offering this month and complete necessary procedures as soon as possible to join the Kosdaq market within this year.
By Park Yoon-gyun and Minu Kim
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]